Modern approach to hepatocellular carcinoma treatment

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-1)

Sum=52

Aug 27, 2025 (publication date) through Aug 27, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Aug 27, 2025; 17(8): 107873
Published online Aug 27, 2025. doi: 10.4254/wjh.v17.i8.107873

Table 1 Summary of the papers regarding the comparison between transarterial radioembolization and transarterial chemoembolization

Ref.	Main aim	Main findings
Salem et al[72]	Glass Y90 TARE (24 pt) vs cTACE (21 pt)	Time to progression: 26 vs 6.8 months (P = 0.0012)
TRACE[73]	Glass Y90 TARE (38 pt) vs DEB-TACE (34 pt)	Median OS: 30.2 months vs 15.6 months
Padia et al[74]	Segmental TARE (104 pt) vs TACE (138)	Overall complete response rate: 84% vs 58% (P < 0.001)
		Median PFS: 564 days vs 271 days (P = 0.002, adjusted P > 0.001)
		OS: 1198 days vs 1043 days (P = 0.35, adjusted P = 0.064)
Biederman et al[75]	Radiation segmentectomy (112 pt) vs TACE (55 pt)	Overall complete response rate: 92.1% vs 52.6% (P = 0.005)
Biederman et al[75]	Radiation segmentectomy (112 pt) vs TACE (55 pt)	Median time to secondary therapy: 812 days vs 161 days (P = 0.001)

OS: Overall survival; PFS: Progression free survival; TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization.

Citation: Cortese F, Anagnostopoulos F, Bazzocchi MV, Caringi S, Pisani AR, Renzulli M, Paraskevopoulos I, Laera L, Surgo A, Spiliopoulos S, Memeo R, Inchingolo R. Modern approach to hepatocellular carcinoma treatment. World J Hepatol 2025; 17(8): 107873
URL: https://www.wjgnet.com/1948-5182/full/v17/i8/107873.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i8.107873